Anavex President & CEO Christopher U. Missling, PhD, to participate in a roundtable discussion at the World Orphan Drug Congress USA, on April 21.
Anavex Life Sciences to Present at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases AD/PD™ 2017
The dual regulation of oxidative stress by SIGMA1 receptors in physiological or pathological conditions
Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP rats
The 13th International Conference on Alzheimer’s and Parkinson’s Diseases, March 29 to April 2, 2017, in Vienna, Austria. Hélène Hall, PharmD, PhD View Presentation
AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP rats
14th International Symposium on Advances in Alzheimer Therapy, Athens, Greece Hall, Hélène; Iulita, M. Florencia; Ducatenzeiler, Adriana; Fisher, Abraham & Cuello, A. Claudio View Poster
Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid
Proceedings of the National Academy of Sciences (May 2015) Shang-Yi A. Tsai, Michael J. Pokrass, Neal R. Klauer, Hiroshi Nohara and Tsung-Ping Su View Paper
Live imaging reveals a new role for the sigma-1 (σ1) receptor in allowing microglia to leave brain injuries
Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper
9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients.
9th Clinical Trials on Alzheimer’s Disease (CTAD) 2016, San Diego, CA Associate Professor Stephen Macfarlane, FRANZCP View Presentation
Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease
World Parkinson Congress 2016, Portland, OR V. Francardo, F. Bez, J. Sprouse, C. Missling, M.A. Cenci View Poster
Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients.
Alzheimer’s Association International Conference 2016, Toronto, Canada Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Christopher U. Missling View Poster
ANAVEX 2‐73 as a Potential Treatment for Rett Syndrome and Other Pediatric or Infantile Disorders with Seizure Pathology.
2016 Rett Syndrome Symposium, Itasca, IL N. Rebowe, J. Sprouse, D. Brunner, P. Kabitzke, L. Velisek, M. Benson, J. Veliskova, C. Missling View Presentation
Sigma-1 Receptor Agonists as Potential Treatment Options for Autism Spectrum Disorders: Pre-clinical Studies with ANAVEX 2-73 in a Fragile X Model.
Gordon Research Conference for Fragile X and Autism-Related Disorders, Mount Snow, VT Patricia Cogram, Daniel Klamer, Nell Rebowe, Jeffrey Sprouse, Christopher U. Missling View Poster
14th International Symposium on Advances in Alzheimer Therapy, Athens, Greece Christopher U. Missling, PhD View Presentation
Anavex Life Sciences Novel Sigma-1 / Sigma-2 Ligand Shows Encouraging Results as an Analgesic in Animal Models of Neuropathic and Visceral Pain
Society for Neuroscience Annual Meeting 2016, San Diego, CA J. Sprouse, N. Rebowe, Y. Darbaky, L. Diop, D. Klamer, C. Missling
Amyloid toxicity induced by oligomeric Aβ25-35 injection is enhanced after pharmacologic or genetic invalidation of the σ1 chaperone protein
Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
Expert Opin Ther Targets. 2011 May ; 15(5): 557–577. doi:10.1517/14728222.2011.560837. Hayashi Teruo*, Tsai Shang-Yi, Mori Tomohisa, Fujimoto Michiko, and Su Tsung-Ping View Poster
Cancer Res 67, 11166-11175, (2007). Palmer, C. P., Mahen, R., Schnell, E., Djamgoz, M. B., & Aydar, E. View abstract in PubMed
J Pharmacol Exp Ther 322, 1278-1285, (2007). Mei, J., & Pasternak, G.W. View abstract in PubMed